How much revenue does RenovaCare make?

RenovaCare reported $0 in revenue for fiscal year 2021. In Q3 2022 revenue was $0.

What companies are similar to RenovaCare?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Valeo Pharma Inc. (VPHIF), Advantis Corp. (ADVT), MJardin Group, Inc. (MJARF), Alliance Growers Corp. (ALGWF).

RenovaCare, Inc. (RCAR) Stock

About RenovaCare, Inc.

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to ...

At a glance

RenovaCare reported revenue of $0 for fiscal year 2021, and net income of -$4.47 million. In Q3 2022 (the quarter ended September 30, 2022) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2021.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.